PDCD1 and non-small cell lung carcinoma: In conclusion, the present meta-analysis demonstrates that anti-PD-1/PD-L1 treatment led to superior survival benefit with an improved safety profile over that for docetaxel in patients with previously treated advanced NSCLC.